The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
 
Neeta DSouza
No Relationships to Disclose
 
Christopher Gaffney
No Relationships to Disclose
 
Christian Hernandez
No Relationships to Disclose
 
Patricia Moran
No Relationships to Disclose
 
Kara Worth
No Relationships to Disclose
 
Melissa McCarter
No Relationships to Disclose
 
Manuel R. de Jesus
No Relationships to Disclose
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Fog Therapeutics; Fore Biotherapeutics; Pfizer; Scorpion Therapeutics; Vividion Therapeutics
 
Judy Sarungbam
No Relationships to Disclose
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Janssen Biotech; PAIGE.AI
 
Bernard H. Bochner
Consulting or Advisory Role - Olympus
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; EMD Serono; Medscape; MJH Life Sciences; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Eugene J. Pietzak
Honoraria - UpToDate
Consulting or Advisory Role - Chugai Pharma; Janssen; Merck; QED Therapeutics; Urogen pharma
Research Funding - Janssen